

Special Issue

Emerging Trends in Lipoprotein and Cardiovascular Diseases

Message from the Guest Editors

High-density lipoproteins (HDL) have a unique lipid metabolism status, and have important clinical implications as biomarkers. It is well known that low HDL cholesterol is a risk factor for atherosclerotic cardiovascular disease; however, many clinical concerns require further investigation. HDL cholesterol interacts, directly or indirectly, with various substances in the blood, as well as with other lipids. Furthermore, HDL cholesterol has several subclasses, and additional research is required to better understand how they work differently to cardiometabolic health issues. Furthermore, detailing implications according to gender, ethnicity, age group, and interrelationships with drugs and nutrition will also be critical biomedical aspects to consider in clinical settings. Beyond the conventional understanding of HDL cholesterol, it is time for advanced research pertaining to technological advances in various clinical contexts. We encourage worldwide participation from researchers interested in cardiovascular and metabolic health.

Guest Editors

Prof. Dr. Yong-Jae Lee

Department of Family Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

Dr. Byoungjin Park

Department of Family Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea

Deadline for manuscript submissions

closed (31 March 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/114908

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).